

FLUCELVAX® QUADRIVALENT (Influenza Vaccine) Coding and Billing



As a cell-based influenza vaccine, FLUCELVAX QUADRIVALENT has a unique Current Procedural Terminology (CPT) code.

Code for the FLUCELVAX QUADRIVALENT vaccine administered

2021-2022 NDC Carton ¹	2021-2022 NDC Unit-of-Use ¹	Presentation ¹	Product Billing CPT Code ²	Description ¹	CVX Code ^{*2}	MVX Code
70461-321-03	70461-321-04	0.5-mL pre-filled syringe	90674	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, contains no preservative or antibiotics, 0.5-mL dosage, for intramuscular use	171	SEQ
70461-421-10	70461-421-11	5-mL multi-dose vial	90756	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, contains no antibiotics, 0.5-mL dosage for intramuscular use	186	SEQ

*CVX=vaccine administered code indicates which product was used and is used in combination with the manufacturer (MVX) code.
NDC=National Drug Code

Note: Some payers may require use of NDCs. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine if the payer requires the 10-digit or 11-digit format. If 11-digit, add a leading zero to the middle section of numbers.

Code for the administration of FLUCELVAX QUADRIVALENT

Report the appropriate administration code in addition to the CPT code for FLUCELVAX QUADRIVALENT.²

Note: Medicare (and some other payers) requires use of the Healthcare Common Procedure Coding System (HCPCS) code, G0008, for administration of preventive vaccines, including influenza, regardless of age. Other payers use the appropriate CPT code based on age and counseling provided.³

Include the appropriate *International Classification of Diseases, Tenth Revision (ICD-10)* diagnosis code

Report the ICD-10 diagnosis code, Z23, indicating an encounter for vaccine administration. The ICD-10 diagnosis code should be linked to both the vaccine and the administration code.³

Determine if modifier 25 is appropriate

When FLUCELVAX QUADRIVALENT is administered on the same date as a significant and separately identifiable Evaluation and Management (E/M) visit, apply modifier 25 to the E/M CPT code, denoting a “significant and separately identifiable” service from the vaccine and vaccine administration service.⁴

CPT Code ⁵	Description
90460	Immunization administration through 18 years of age (via any route of administration) with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
90461 (add-on code)	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) NOTE: Report this code for immunization administration of any vaccine that is not accompanied by face-to-face physician or other qualified health care professional counseling the patient and/or family, or for patients over 18 years of age.
HCPCS Code ⁶	Description
G0008	Seasonal influenza virus vaccine administration
ICD-10 Code ³	Description
Z23	Encounter for immunization

Visit flu.seqirus.com for additional resources and information.

Please see Important Safety Information on next page, and the full US Prescribing Information for FLUCELVAX QUADRIVALENT.

For US Healthcare Professional Use Only
This information does not constitute a guarantee or warranty of coverage benefits or reimbursement

Questions?



Call flu360 | Support
(855) 358-8966, option 2

FLUCELVAX® QUADRIVALENT (Influenza Vaccine)

IMPORTANT SAFETY INFORMATION



INDICATION AND USAGE

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 2 years of age and older.

CONTRAINDICATIONS

Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine.

WARNINGS & PRECAUTIONS

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUCELVAX QUADRIVALENT. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position.

After vaccination with FLUCELVAX QUADRIVALENT, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.

Vaccination with FLUCELVAX QUADRIVALENT may not protect all vaccine recipients against influenza disease.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided "as is" and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.

References: **1.** FLUCELVAX QUADRIVALENT. Package insert. Seqirus Inc; 2021. **2.** Centers for Disease Control and Prevention. CPT codes mapped to CVX codes. Accessed May 3, 2021. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt> **3.** Centers for Medicare & Medicaid Services. Flu shot & administration. Accessed May 3, 2021. <https://www.cms.gov/Medicare/Prevention/PreventionGenInfo/medicare-preventive-services/MPS-QuickReferenceChart-1.html#FLU> **4.** American Medical Association. Current Procedural Terminology 2021 (Professional Edition). American Medical Association; 2020. **5.** American Academy of Pediatrics. Coding for pediatric preventive care 2021. Accessed May 3, 2021. https://www.aap.org/en-us/Documents/coding_preventive_care.pdf

flu360™, FLUCELVAX® QUADRIVALENT, and WE'VE GOT FLU COVERED™ are trademarks of Seqirus UK Limited or its affiliates.
Seqirus USA Inc., 25 DeForest Avenue, Summit, NJ 07901, USA
©2021 Seqirus USA Inc. July 2021 USA-FLU360-21-0118



ADVERSE REACTIONS

In adults 18 through 64 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain ($\geq 40\%$), erythema and induration ($\geq 10\%$). The most common systemic adverse events were headache, fatigue and myalgia ($\geq 10\%$).

In adults ≥ 65 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were pain ($\geq 20\%$) and erythema ($\geq 10\%$).

In children 2 through 8 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28.7%), pain (27.9%) and erythema (21.3%), induration (14.9%) and ecchymosis (10.0%). The most common systemic adverse events were sleepiness (14.9%), headache (13.8%), fatigue (13.8%), irritability (13.8%) and loss of appetite (10.6%).

In children and adolescents 9 through 17 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were injection site pain (21.7%), erythema (17.2%) and induration (10.5%). The most common systemic adverse events were headache (18.1%) and fatigue (17.0%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the [full US Prescribing Information](#) for FLUCELVAX QUADRIVALENT.

FLUCELVAX® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.